New trends in the treatment of Hodgkin's disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 11025246.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Over the past several years, much progress has been made in the treatment of Hodgkin's disease (HD), with 5-year overall survival rates ranging from 60 to 95%, according to initial prognostic factors. This optimism has been tempered by the development of late complications in long-term HD survivors, in particular second neoplasms and cardiac toxicity. At present, new treatments aimed at maintaining high event-free survival and reducing long-term adverse effects are being studied. To be successful, the treatment must be tailored according to prognostic factors.